Conagra Brands (CAG) Financials

Conagra Brands’ latest quarter shows an earnings recovery, but underlying operating and cash-flow trends remain mixed. In Q1 fiscal 2027, revenue declined 1.4% year over year to $2.60 billion, while gross profit fell 3.4% to $618.7 million. Operating income decreased 12.0% to $268.4 million, reflecting a decline in operating margin to approximately 10.3% from 11.6% in Q1 fiscal 2026.

Despite the weaker operating performance, net income increased to $174.3 million from $164.5 million, and diluted earnings per share rose to $0.36 from $0.34. This follows two loss-making quarters in fiscal 2026 and a sizable $1.62 billion loss in Q4 fiscal 2026, primarily associated with impairment-related charges. The latest quarter therefore indicates a return to profitability, although earnings remain below the levels reported in fiscal 2024 and early fiscal 2025.

• Return to profitability: Q1 fiscal 2027 net income was $174.3 million, compared with losses in Q2 and Q4 fiscal 2026. Diluted EPS improved to $0.36 from $0.34 a year earlier.
• Lower debt balances: Total short- and long-term debt declined to approximately $7.76 billion in Q1 fiscal 2027 from $8.28 billion in Q1 fiscal 2026, supported by debt repayments during the period.
• Reduced goodwill and intangible asset exposure: Goodwill declined from $10.50 billion in Q1 fiscal 2026 to $8.12 billion, while intangible assets fell from $2.41 billion to $1.82 billion. This reflects the recognition of prior impairment charges and reduces the balance-sheet risk associated with these assets.
• Ongoing shareholder returns: Conagra paid $167.5 million in dividends and repurchased $44 million of stock during the latest quarter. The quarterly dividend remained $0.35 per share, above the $0.33 per-share payment reported in fiscal 2023.
• Capital investment remains active: Capital expenditures were $123.7 million in Q1 fiscal 2027, up from $95.6 million in Q1 fiscal 2026, indicating continued investment in property, plant and equipment.
• Working-capital pressure: Inventories increased to $2.15 billion from $2.26 billion a year earlier, while accounts receivable declined to $677 million from $757 million. The inventory reduction is constructive, but operating working-capital changes still consumed $229.3 million of cash in the latest quarter.
• Financing supported liquidity: Cash and equivalents increased sequentially to $371.6 million from $55.1 million at the end of Q3 fiscal 2026, but the improvement was aided by $525.2 million of new debt issuance rather than operating cash generation.
• Revenue remains below prior-year levels: Q1 fiscal 2027 revenue of $2.60 billion was down from $2.63 billion a year earlier and well below the roughly $3.0 billion quarterly revenue levels recorded during much of fiscal 2023 and fiscal 2024.
• Operating margins are contracting: Gross margin declined to approximately 23.8% from 24.3% year over year, while operating margin fell to approximately 10.3% from 11.6%. This suggests continued pressure from product mix, pricing, costs or volume.
• Weak operating cash flow and limited liquidity: Operating activities used $4.2 million of cash in Q1 fiscal 2027, compared with $120.6 million generated a year earlier. With $3.36 billion of current assets versus $3.07 billion of current liabilities, the current ratio was only about 1.1, leaving limited room for sustained cash-flow weakness.

Overall, the statements point to a company emerging from a major impairment-driven downturn, with profitability and debt metrics improving from fiscal 2026’s weakest periods. However, declining revenue and margins, negative quarterly operating cash flow, substantial dividend commitments and reliance on debt issuance remain important risks for investors to monitor.